CLOSE MENU
Rapid Typhoid Detection
Diagnostics for oncology
Privacy Policy for IDL Biotech AB
All rights reserved 2021 © IDL Biotech AB (publ)
IDL Biotech has now received its first order from the company's distributor in Uganda, Medilink Lab & Surgical Ltd. The order refers to TUBEX® TF, IDL Biotech's rapid test for typhoid fever. Uganda will thus be the third country in Africa to which the company delivers TUBEX® TF.
IDL Biotech continues to expand in Africa. IDL Biotech has signed a distributor agreement with Res Health Consult Ltd covering Ghana. The agreement covers the sale of TUBEX® TF.
IDL Biotech currently has a number of ongoing clinical studies both internationally and in Sweden, with the aim of demonstrating the clinical benefit of UBC® Rapid in bladder cancer and having the test included as a complement in the follow-up of patients with bladder cancer who are classified as high risk.
IDL Biotech continues to expand in Africa. Today, IDL Biotech has signed a distributor agreement with Roi Scientific Ltd covering Rwanda, South Sudan and Somalia. The agreement covers the sale of TUBEX® TF.
As previously informed, at the end of 2019, IDL Biotech signed a cooperation agreement with the Chinese company Zecen Biotech, regarding automation of the tumor marker TPS® on all Zecen Biotech's instruments. The development project has proceeded very well and the first phase has been completed. Thus, the last phase before launch now begins. The hope is that the product will be available on the Chinese market by the end of 2021.
“IDL Biotech wants to focus on rapid diagnostic tests and automated assays of its tumor markers. By licensing the platform ELISA to Beckman Coulter, we can focus our resources on streamlining and developing the other platforms,” said Gunnar Wahlberg, CEO of IDL Biotech.
In recent years IDL Biotech has been working on developing a rapid test to detect lung cancer, under the project name MonoTotal® Rapid. However, further development will instead focus on creating a rapid test for breast cancer.
I enlighet med beslut vid årsstämman som hölls den 27 maj 2020 har styrelsens ordförande i IDL Biotech tillsett att bolagets röstmässigt tre största aktieägare har erbjudits att vardera utse varsin representant att ingå i valberedningen.
Gunnar Wahlberg was appointed as the new CEO of IDL Biotech from the 1st of December 2020. Gunnar has served as acting CEO since the 1st of September after the previous CEO left the post on the 31st of August. Gunnar Wahlberg has previously been a part of IDL Biotech group executive board and worked as Head of Sales since spring of 2019.
In 2019, IDL Biotech submitted a so-called “Pre-submission request” to the US FDA (United States Food and Drug Administration) this was done to ensure the future approval of UBC® Rapid, the company’s rapid diagnostic test for bladder cancer. As of now, the company is proceeding with preparations of clinical trial in the United States of America.
The Board has appointed Gunnar Wahlberg as acting CEO.
IDL is proud to announce that Jeanpierre Salas Montes will take over as production manager at IDL Biotech. Ola Eklund has decided to retire after more than 20 years at IDL.
IDL Biotech's CEO, Charlotte Berg, has informed the Board that, after more than ten years at the company, she wishes to resign as CEO to start another assignment in a non-competing company.
IDL Biotech has appointed Subyung Park as Business Development Manager Asia with a focus on the product TUBEX® TF.
A publication presented in Entropy shows the value of UBC® Rapid
Årsstämma hålls den 27 maj 2020 kl. 15.00 på Piperska Muren, Scheelegatan 14, 112 28 Stockholm.
Beckman Coulter has been one of IDL Biotech's most successful tumor markers distributors, and has sold the products in the Czech Republic and Slovakia for many years. With Beckman Coulter now taking over the global distribution rights for the company's tumor markers, we can intensify our focus on rapid testing and automation. At the same time, it gives Beckman Coulter the opportunity to broaden his product portfolio within tumor markers, ”says Charlotte Berg, CEO of IDL Biotech. IDL Biotech will continue to produce the tumor markers. The agreement is global, excluding the Chinese market.
IDL Biotech continues to expand in Africa. IDL Biotech has signed a distributor agreement with PHM Diagnostic Lab Ltd in Zimbabwe.
The registration of TUBEX TF has been approved in Indonesia.
IDL has signed a distribution agreement in Malaysia
Achieving accurate laboratory diagnosis of typhoid fever: a review and meta-analysis of TUBEX® TF clinical performance.
IDL has signed a new distribution agreement in Uganda
IDL has signed two new distributions agreements.
IDL Biotech fortsätter förstärka sitt globala team. Sam Kariuki, med över trettio års erfarenhet inom tropisk medicin, är ny Vetenskaplig Rådgivare till bolaget.
I juli lämnade IDL Biotech in underlag, så kallad Pre-submission request, till amerikanska FDA (Food and Drug Administration) för att kunna få ett framtida godkännande för försäljning i USA av UBC® Rapid, bolagets snabbtest för blåscancer. Idag genomfördes det första uppföljningsmötet med FDA.
IDL Biotech meddelar att de har tecknat ett avtal med Beckman Coulter om licensiering av IDL Biotechs samtliga tumörmarkörer på den manuella plattformen radioimmunoassay (IRMA). Licensavtalet ger Beckman Coulter globala försäljningsrättigheter och möjliggör för IDL att erhålla royalties. Avtalet har formellt undertecknats av Immunotech, ett dotterbolag till Beckman Coulter.
IDL will participate at Svenska Urologidagarna 2-4 October 2019 at Aros Congress Center. IDL will also be presented at Medica i Düsseldorf, 18-21 November 2019 in Hall 1 at location D34 . We are looking forward to meeting you there.!
IDL Biotech has started the work on mapping the US market.
On September 17, 2019, IDL Biotech will launch the company's rapid test for typhoid fever, TUBEX TF, in Kenya.
The annual general meeting, held 28th of May 2019, re-elected Jerker Swanstein, Per-Anders Abrahamsson and Carsten Olsson, and elected Malin Ruijsenaars and Eva Sjökvist Saers as new members of the Board of Directors. During the statutory meeting held 28th of May 2019 Jerker Swanstein was selected as new Chairman of the Board of Directors.
The Annual General meeting was held on the 28th of May 2019.
The shareholders of IDL Biotech AB (publ) are hereby invited to the Annual General Meeting on Tuesday, 28 May 2019, 15.00 at Redeye AB, Mäster Samuelsgatan 42, 10387 Stockholm.
Spotlight has produced a short film about IDL Biotech.
Every two years, the Coalition against Typhoid, based at the Sabin Vaccine Institute (Sabin), convenes the International Conference on Typhoid and Other Invasive Salmonelloses. The 11th International Conference on Typhoid and Other Invasive Salmonelloses will be held from March 26-28, 2019 in Hanoi, Vietnam. IDL Biotech is proud to be a sponsor of this important conference.
CEO Charlotte Berg is interviewed in the latest podcast from SvD Börspluspod.
Börshajen has published an interview with Charlotte Berg, CEO at IDL Biotech.
IDL Biotechs extra ordinary general meeting held on the 25th October 2018 decided to establish a nomination committee.
International Journal of Molecular Sciences has published a study on UBC® Rapid. In total 530 urine samples was included in the multicenterstudy.
On Saturday the 17th of November, the Swedish newspaper SvD, had an interview with the CEO, Charlotte Berg.
Styrelsen i IDL Biotech AB (Publ) har upprättat ett prospekt med anledning av den förestående nyemissionen med företrädesrätt för IDL Biotechs aktieägare. Prospektet har idag godkänts och registrerats av Finansinspektionen.
The Extraordinary meeting was held on 2018-10-26.
IDL Biotech will attend Redeye Life Science Day on November 21, at Haymarket City Scandic Stockholm, Hötorget 13-15, Stockholm. Charlotte Berg, CEO, will have her presentation at 1 pm. The presentation is live on www.redeye.se/live/lsday-2018. You can follow the presentation through the computer or cellphone.
IDL has appointed Nick Thilveris as our new Regional Manager Asia Pacific
The Extra Annual General Meeting will be held 25th of October.
The board of directors of IDL Biotech AB (publ) has resolved to make a new share issue of approximately SEK 39,4 million before issue costs.
IDL Biotech today announced that they are strengthening their global Sales and Marketing team. Martyn Eales has been named Senior Vice President of Global Sales and Marie Torstensson has been named Marketing Manager. Together they will lead the effort to increase international sales.
During 2015 the patent ”Method for detection of cytokeratin 8, 18 and/or 19 and/or soluble fragments thereof” was approved in Sweden. In September 2017 the patent was approved in China. The patent has now also been approved in Europe and is valid until 2034.
Per-Anders Abrahamsson, MD, PhD, Professor in Urology, has been working as urologist for 40 years, out of which 20 years as Head of the Department of Urology, Skåne University Hospital (Malmö/Lund, Trelleborg and Landskrona), Adjunct Secretary General at the European Association of Urology (EAU) 2004-2007 responsible for Science, EAU Secretary General 2007 – 2015, Vice President Global Medical Affairs Uro-oncology, Ferring Pharmaceuticals A/S and Member of the Board at Camurus AB.
One in three people in Sweden will develop cancer in their life time. Rehabilitation can help cancer patients to recover, both mentally and physically. CancerRehabFonden is an Swedish independent organization that provides cancer rehabilitation free of charge.
Results from a Czech Republic study.
IDL Biotech continues to strengthen its scientific knowledge by appointing an additional experienced scientific advisor.
International Journal of Medical Sciences has published an Austrian study with UBC® Rapid performed at the Department of Urology, Medical University of Innsbruck. Urinary samples were analyzed by cytology, UBC® Rapid and NMP22 BladderChek® test.
Results from a published multicenter study
The annual general meeting, held 23rd of May 2017, approved the re-election of Jerker Swanstein, Max Pihlqvist, Hans Örström and Peter Brätuigam. During the statutory meeting held 24th of May 2017 Hans Örström was selected as new Chariman of the Board.
The study published in Scandinavian Journal of Urology (https://www.ncbi.nlm.nih.gov/pubmed/28422550) was conducted at four Swedish hospitals; Uppsala University Hospital, Danderyds hospital, Enköping Hospital and Umeå University Hospital. Principal investigators was Assoc. Prof Amir Sherif, Umeå University.
Result from a new German multicenter study
TUBEX® is getting wider recognition and awareness – Now on social Media.
IDL Biotech tumor marker MonoTotal® ELISA has been registered by the Swedish Medical Product Agency for the use in the EU.
Evaluation of bladder cancer with point-of-care (POC) tests depends on the detection of bladder cancer associated proteins in urine samples.
